Síndrome de Guillain-Barré com flutuações relacionadas ao tratamento com imunoglobulina humana endovenosa (curso trifásico): relato de caso

Arquivos de Neuro-Psiquiatria 01/1998; DOI: 10.1590/S0004-282X1998000300020
Source: DOAJ

ABSTRACT Os autores apresentam um caso de síndrome de Guillain-Barré (SGB), com tetraplegia e ventilação mecânica, que foi tratado com imunoglobulina humana endovenosa (IgEV), 2 g/kg, apresentando melhora clínica inicial, tendo piorado na segunda semana. Foi realizada uma segunda sessão de IgEV, também com melhora inicial, seguida de piora aos 65 dias de doença. Uma terceira etapa de IgEV foi realizada, sendo a melhora definitiva e sem outros episódios após 3 anos de seguimento. Os autores revisam a literatura sobre flutuações relacionadas ao tratamento. Concluem que na SGB é importante uma observação clínica rigorosa nas primeiras semanas após tratamento com IgEV e que seriam necessários estudos para elaborar protocolos alternativos de prevenção nesses casos.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In the second part of our review the role of antecedent infections in the pathogenesis of GBS is discussed. The association with Campylobacter jejuni (C. jejuni) is highlighted and the concept of molecular mimicry, i.e., sharing of epitopes between microbes and peripheral nerve, explained. Alternative mechanisms to relate an infection with the immune-mediated neuropathy are elaborated. Current therapies of the GBS include plasma exchange, high-dose intravenous immunoglobulins, and supportive treatment directed to secondary complications. Published therapeutic trials are reviewed and future approaches are outlined. Principles of general care are also summarized.© 1995 John Wiley &Sons, Inc.
    Muscle & Nerve 10/2004; 18(2):154 - 164. · 2.31 Impact Factor
  • New England Journal of Medicine 05/1992; 326(17):1130-6. · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Better outcomes for patients with Guillain-Barré syndrome are associated with five factors: younger age, no requirement for respiratory assistance, slower progression of disease, normal peripheral nerve function by electrodiagnostic criteria, and treatment by plasmapheresis. Plasmapheresis is the only factor that the treating physician can modify. Consideration of the use of plasmapheresis in children, type of replacement fluid, plasma exchange by simpler methods than plasmapheresis, and possible alternative approaches to therapy are discussed.
    Annals of Neurology 12/1989; 27(S1):S13 - S16. · 11.19 Impact Factor


Available from